Concurrent dendritic cell vaccine and strontium-89 radiation therapy in the management of multiple bone metastases

Irish Journal of Medical Science

Volumn 184, Issue 2, 2015, Pages 457-461

  Liu, J ^a   Li, J ^b,c   Fan, Y ^b   Chang, K ^a   Yang, X ^b,c   Zhu, W ^b   Wu, X ^b   Pang, Yan ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Tianjin Union Medicine Centre   (China)

^c Shanghai Claison Biotechnology Co Ltd   (China)

Author keywords

Bone metastases; Cancer; Combination therapy; DC vaccine; Immunotherapy; Strontium 89

Indexed keywords

CANCER VACCINE; STRONTIUM; STRONTIUM CHLORIDE;

ADVERSE EFFECTS; AGED; ANALGESIA; BONE NEOPLASMS; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES; QUALITY OF LIFE; SECONDARY; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; BONE NEOPLASMS; CANCER VACCINES; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; MALE; MIDDLE AGED; PAIN MANAGEMENT; QUALITY OF LIFE; STRONTIUM; STRONTIUM RADIOISOTOPES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84939883015     PISSN: 00211265     EISSN: 18634362     Source Type: Journal    
DOI: 10.1007/s11845-014-1145-9     Document Type: Article

References (29)

1. Petrut B, Trinkaus M, Simmons C et al (2008) A primer of bone metastases management in breast cancer patients. Curr Oncol 15:S50–S57. doi:10.3747/co.2008.176
2. Sartor AO (2011) Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol 4:18
3. Gridley DS, Williams JR, Slater JM (2005) Low-dose/low-dose-rate radiation: a feasible strategy to improve cancer radiotherapy? Cancer Ther 3:105–130
4. Reddy EK, Robinson RG, Mansfield CM (1986) Strontium 89 for palliation of bone metastases. J Natl Med Assoc 78:27–32
5. Lewington VJ (1993) Targeted radionuclide therapy for bone metastases. Eur J Nucl Med 20:66–74. doi:10.1007/BF02261248
6. Kraeber-Bodéré F, Campion L, Rousseau C et al (2000) Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med 27:1487–1493. doi:10.1007/s002590000315
7. Buchali K, Correns HJ, Schuerer M et al (1988) Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 14:349–351
8. Pons F, Herranz R, Garcia A et al (1997) Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med 24:1210–1214. doi:10.1007/s002590050143
9. Kasalický J, Krajská V (1988) The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med 25:1362–1367
10. Soliman H (2010) Developing an effective breast cancer vaccine. Cancer Control 17:183–190
11. Nguyen-Pham TN, Lee YK, Lee HJ et al (2012) Cellular immunotherapy using dendritic cells against multiple myeloma. Korean J Hematol 47:17–27. doi:10.5045/kjh.2012.47.1.17
12. Thomas-Kaskel AK, Zeiser R, Jochim R et al (2006) Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer 119:2428–2434. doi:10.1002/ijc.22097
13. Kiessling A, Füssel S, Wehner R et al (2008) Advances in specific immunotherapy for prostate cancer. Eur Urol 53:694–708. doi:10.1016/j.eururo.2007.11.043
14. Kim CH, Woo SJ, Park JS et al (2007) Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma. Immunology 122:615–622. doi:10.1111/j.1365-2567.2007.02680.x
15. Nguyen-Pham TN, Lee YK, Kim HJ et al (2012) Immunotherapy using dendritic cells against multiple myeloma: how to improve? Clin Dev Immunol 2012:397648. doi:10.1155/2012/397648
16. Sharp HJ, Wansley EK, Garnett CT et al (2007) Synergistic antitumor activity of immune strategies combined with radiation. Front Biosci 12:4900–4910. doi:10.2741/2436
17. Tseng CW, Trimble C, Zeng Q et al (2008) Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunol Immunother 58:737–748. doi:10.1007/s00262-008-0596-0
18. Finkelstein SE, Timmerman R, McBride WH et al (2011) The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol 2011:439752. doi:10.1155/2011/439752
19. Persson BRR, Koch CB, Grafström G, et al. (2011) “Abscopal” effect of radiation therapy combined with immune-therapy using IFN-γ gene transfected syngeneic tumor cells, in rats with bilateral implanted N29 tumors. ISRN Immunol 230130. doi:10.5402/2011/230130
20. Reissfelder C, Timke C, Schmitz-Winnenthal H et al (2011) A randomized controlled trial to investigate the influence of low dose radiotherapy on immune stimulatory effects in liver metastases of colorectal cancer. BMC Cancer 11:419. doi:10.1186/1471-2407-11-419
21. Liu Y, Zhang W, Zhang B et al (2013) DC vaccine therapy combined concurrently with oral capecitabine in metastatic colorectal cancer patients. Hepatogastroenterology 60:23–27. doi:10.5754/hge12522
22. Luo J, Sun Y, Wu G et al (1996) Development and assessment of quality of life questionnaire for Chinese cancer patients. J Pract Oncol 11:252–254
23. Hovey E, Marx G, Kneebone A et al (2009) An Australian clinical perspective: management of hormone refractory (androgen-independent) prostate cancer. Asia Pac J Oncol Hematol 1:77–88
24. Ma Y, Kepp O, Ghiringhelli F et al (2010) Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol 22:113–124. doi:10.1016/j.smim.2010.03.001
25. Lin CC, Wang TE, Liu CY et al (2008) Potentiation of the immunotherapeutic effect of autologous dendritic cells by pretreating hepatocellular carcinoma with low-dose radiation. Clin Invest Med 31:E150–E159
26. Chakraborty M, Wansley EK, Carrasquillo JA et al (2008) The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clin Cancer Res 14:4241–4249. doi:10.1158/1078-0432.CCR-08-0335
27. Teitz-Tennenbaum S, Li Q, Davis MA et al (2009) Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer. J Immunother 32:602–612. doi:10.1097/CJI.0b013e3181a95165
28. Ridolfi L, Petrini M, Fiammenghi L et al (2010) Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis. Clin Dev Immunol 2010:504979. doi:10.1155/2010/504979
29. Rotow J, Gameiro SR, Madan RA et al (2010) Vaccines as monotherapy and in combination therapy for prostate cancer. Clin Transl Sci 3:116–122. doi:10.1111/j.1752-8062.2010.00186.x